Skip to main content
. 2020 Mar 18;10(3):e034716. doi: 10.1136/bmjopen-2019-034716

Figure 4.

Figure 4

Sensitivity analyses: incremental costs per person over a lifetime for the Ad Hoc Testing strategy versus the No Testing strategy. GCK, glucokinase.